FDA Targets Pharmacy for Copying Blockbuster Drugs

The Food and Drug Administration (FDA) has formally warned Empower Pharmacy, a major compounding facility, for allegedly violating federal law by producing copies of popular weight-loss drugs in excessive quantities. This warning letter, dated September 18, 2026, signifies the FDA's initial direct involvement in the contentious issue of when a pharmacy's practice of customizing medications crosses into mass-producing replicas of patented drugs.

Compounding pharmacies traditionally tailor medications for individual patient needs. However, the recent surge in demand for GLP-1 weight-loss drugs presented an opportunity. When the FDA declared shortages of these medications in 2022, many compounding pharmacies began producing their own versions, offering them at significantly lower prices. This practice continued even after the FDA declared the shortage ended in 2025, with some pharmacies altering dosages or adding vitamins to comply with FDA policies for individual patient variations.

Pharmaceutical giants Eli Lilly and Novo Nordisk have vocally opposed these practices, leading to ongoing litigation. Eli Lilly alleges that Empower Pharmacy is deceptively marketing standardized knockoffs under the guise of personalized products. The FDA's action, following an inspection in November 2025, determined that Empower was using a pretext for large-scale copying. Experts suggest this FDA stance may narrow the scope for compounded weight-loss drugs.